Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.75 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.72 |
| ▸ | PPARG | P37231 | 4/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.61 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.61 |
| ▸ | CREB1 | P16220 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376090 | 1.00 | L3MBTL1 (0.77) | L3MBTL1KDM4EABCG2ALDH1A1NPC1 | |
| SCHEMBL29979584 | 0.92 | L3MBTL1 (0.79) | L3MBTL1KDM4EABCG2ALDH1A1NPC1 | |
| SCHEMBL8064295 | 0.91 | L3MBTL1 (0.71) | L3MBTL1KDM4EABCG2ALDH1A1NPC1 | |
| SCHEMBL8066758 | 0.90 | L3MBTL1 (0.72) | L3MBTL1KDM4EABCG2ALDH1A1NPC1 | |
| SCHEMBL20613656 | 0.87 | L3MBTL1 (0.62) | L3MBTL1KDM4EABCG2ALDH1A1NPC1 | |
| SCHEMBL4268322 | 0.87 | L3MBTL1 (1.00) | L3MBTL1KDM4EABCG2ALDH1A1NPC1 | |
| Chrysin Dimethyl Ether SCHEMBL1676012 | 0.86 | ABCG2 (1.00) | KDM4EABCG2ALDH1A1NPC1MEN1 | |
| Chrysin Dimethyl Ether SCHEMBL29403280 | 0.86 | ABCG2 (1.00) | KDM4EABCG2ALDH1A1NPC1MEN1 | |
| SCHEMBL1421600 | 0.85 | ABCG2 (0.67) | L3MBTL1KDM4EABCG2ALDH1A1NPC1 | |
| SCHEMBL738489 | 0.84 | MEN1 (0.71) | L3MBTL1ABCG2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115213-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-20250361218-A1 | AGENTS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-11-27 | — | — | US | disclosed |
| EP-3755693-B1 | AGENTS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4322940-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | Memorial Sloan-Kettering Cancer Center (US) | 2024-02-21 | — | — | EP | disclosed |
| CN-116768839-A | Synthesis method of oroxylin | 南京芩领医药科技有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-111836808-B | Novel compound for preventing, alleviating or treating fibrosis or nonalcoholic steatohepatitis and composition comprising the same as active ingredient | 欧斯特奥纽罗根有限公司 | 2023-04-28 | — | — | CN | disclosed |
| WO-2022221519-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-3760626-B1 | NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT | OSTEONEUROGEN INC (KR) | 2022-05-18 | — | — | EP | disclosed |
| CN-112351977-A | Agents and methods for treating abnormal proliferative diseases | 纪念斯隆凯特林癌症中心 | 2021-02-09 | — | — | CN | disclosed |
| EP-3760626-A1 | NOVEL COMPOUND AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS OR NONALCOHOLIC STEATOHEPATITIS COMPRISING SAME AS ACTIVE INGREDIENT | Osteoneurogen Inc. (KR) | 2021-01-06 | — | — | EP | disclosed |
| CN-111836808-A | Novel compound for preventing, alleviating or treating fibrosis or nonalcoholic steatohepatitis and composition comprising same as active ingredient | 欧斯特奥纽罗根有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10744114-B2 | Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity | OSTEONEUROGEN INC. (KR) | 2020-08-18 | — | — | US | disclosed |
| US-10744113-B2 | Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity | OSTEONEUROGEN INC. (KR) | 2020-08-18 | — | — | US | disclosed |
| US-20190263789-A1 | SUBSTITUTED CHROMENES FOR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS | OSTEONEUROGEN INC. (KR) | 2019-08-29 | — | — | US | disclosed |
| WO-2019161345-A1 | AGENTS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-08-22 | — | — | WO | disclosed |
| US-10370364-B1 | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | OSTEONEUROGEN INC. (KR) | 2019-08-06 | — | — | US | disclosed |
| US-20190231739-A1 | NEW USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2019-08-01 | — | — | US | disclosed |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | OSTEONEUROGEN INC. (KR) | 2017-08-24 | — | — | US | disclosed |
| CN-101508689-B | Synthesis of oroxylin | UNIV CHINA PHARMA | 2010-12-08 | — | — | CN | disclosed |
| CN-101508689-A | Synthesis of oroxylin | UNIV CHINA PHARMA (CN) | 2009-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115213-A1 | SYNTHETIC ROCAGLATES WITH BROAD-SPECTRUM ANTIVIRAL ACTIVITIES AND USES THEREOF | SARS1, RNGTT, NSUN3 | L3MBTL1 77/4885KDM4E 2036/4885ABCG2 750/4885 |
| US-10370364-B1 | Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis | CYP7A1, NR1H3, CES1 | L3MBTL1 1742/4885KDM4E 1469/4885ABCG2 1800/4885 |
| US-20190231739-A1 | NEW USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | L3MBTL1 4140/4885KDM4E 1246/4885ABCG2 2176/4885 |
| US-10744113-B2 | Use of chromone derivative as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity | CDH1, SMAD3, SMAD2 | L3MBTL1 3847/4885KDM4E 1217/4885ABCG2 2107/4885 |
| US-20190263789-A1 | SUBSTITUTED CHROMENES FOR TREATMENT OF FIBROSIS OR NON-ALCOHOLIC STEATOHEPATITIS | VIM, HNF4A, CDH1 | L3MBTL1 2607/4885KDM4E 1017/4885ABCG2 2016/4885 |
| US-20250361218-A1 | AGENTS AND METHODS FOR TREATING DYSPROLIFERATIVE DISEASES | RB1, QDPR, EDNRA | L3MBTL1 3299/4885KDM4E 4639/4885ABCG2 2241/4885 |
| US-20170239211-A1 | USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY | CDH1, SMAD3, SMAD2 | L3MBTL1 3847/4885KDM4E 1217/4885ABCG2 2107/4885 |
| US-10744114-B2 | Use of eupatilin as pharmaceutical composition for prevention and treatment of fibrosis using EMT inhibitory activity | SMAD2, CDH1, SMAD3 | L3MBTL1 4199/4885KDM4E 2195/4885ABCG2 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.